Log In
Print
BCIQ
Print
Print this Print this
 

vigabatrin (CPP-109)

  Manage Alerts
Collapse Summary General Information
Company Catalyst Pharmaceutical Partners Inc.
DescriptionIrreversible inhibitor of GABA transaminase
Molecular Target GABA transaminase
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationTourette's syndrome
Indication DetailsTreat Tourette's disorder
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today